An announcement from Day One Biopharmaceuticals (DAWN) is now available.
Day One Biopharmaceuticals, Inc. successfully sold a Rare Pediatric Disease Priority Review Voucher for $108 million in cash, which included an $8.1 million payout to Viracta Therapeutics as per prior agreements. The voucher, which expedites FDA review for treatments like the company’s recently approved OJEMDA™ for a type of pediatric brain cancer, was part of a move to stimulate development in the field of rare pediatric diseases. Following this transaction, the company announced the deal and updated its corporate presentation, emphasizing that this information would not be considered filed under U.S. securities laws.
For a thorough assessment of DAWN stock, go to TipRanks’ Stock Analysis page.
